HK:2196 Shanghai Fosun Pharmaceutical (Group) Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, engages in the research, development, manufacture, trade, and sale of pharmaceutical products in Mainland China and internationally. It offers metabolism and alimentary system drugs for the treatment of chronic hepatitis B, diabetes, chronic atrophic gastritis and gastralgia, hyperuricemia with the symptom of gout, anemia, heart-liver fire, constipation, and abdominal distension; and anti-infection drugs to treat malaria, cefmetazole sodium, tuberculosis, sensitive gram-positive bacterial infections, and viral pneumonia and upper respiratory tract infections. The company also provides cardiovascular and blood system drugs for coronary heart disease, asystole, cardiac failure, cardiacarrhythmia, sinus syndrome, hypertension, and renal failure, as well as for various dialysis treatments. In addition, it offers anti-tumor drugs for the treatment of lung, breast, prostate, gastric, colorectal, and nasopharyngeal cancers, as well as for malignant pleural mesothelioma; and vaccines for the prevention of influenza. Further, the company provides central nervous system drugs; and API and intermediates. Additionally, it develops, manufactures, imports, exports, and sells medical equipment and diagnostic products; provides healthcare, hospital management, and consulting services; and researches and develops biopharmaceutical and chemical drugs. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

27.85 HKD
As of 08/12/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Index country:  China
Country of incorporation:  China
IPO date:  10/30/2012
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   0 HKD
Current dividend yield:   0.00%
Sedol:      B8XBQ96

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy